| Article Access Statistics|
| Viewed||277 |
| Printed||3 |
| Emailed||0 |
| PDF Downloaded||8 |
| Comments ||[Add] |
Click on image for details.
|Year : 2019 | Volume
| Issue : 1 | Page : 335
Antibodies to dengue, Zika, Campylobacter jejuni and gangliosides in Guillain-Barre syndrome
Pathum Sookaromdee1, Viroj Wiwanitkit2
1 Medical Center, TWS Medical Center, Bangkok, Thailand
2 Department of Biological Science, Joseph Ayobabalola University, Nigeria
|Date of Web Publication||7-Mar-2019|
Dr. Pathum Sookaromdee
TWS Medical Center, Bangkok - 02-2134567
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Sookaromdee P, Wiwanitkit V. Antibodies to dengue, Zika, Campylobacter jejuni and gangliosides in Guillain-Barre syndrome. Neurol India 2019;67:335
We read the publication on “Antibodies to Zika virus, Campylobacter jejuni and gangliosides in Guillain-Barre syndrome (GBS): A prospective single-center study from southern India” with a great interest. Baskar et al., noted that “Our study had a high prevalence of anti-C. jejuni and anti-ganglioside antibodies ” and “Whether this represents cross-reaction with dengue or prior/co-infection with dengue virus could not be addressed in this study.” We would like to share ideas and experience of this study. First, in our setting, the concurrent infection between dengue and Zika virus is not uncommon and the detection of seropositivity to both dengue and Zika virus is reported. In addition, the additional seropositivity to Chikungunya virus is also observable. The similar concurrent seropositivity to other common tropical disorders can also be expected. Since the arbovirus is very common in tropical countries, the seropositivity to several viruses among local people might be expected. It should be noted that although the Zika virus seropositivity is high in our setting, but the case is usually asymptomatic., There is lack of clinical observation between infection or seropositivity and GBS. There should be other genetic or epigenetic factors that might result in the GBS in Zika infected case in some regions of the world.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| » References|| |
Baskar D, Amalnath D, Mandal J, Dhodapkar R, Vanathi K. Antibodies to Zika virus, Campylobacter jejuni and gangliosides in Guillain-Barre syndrome: A prospective single-center study from southern India. Neurol India 2018;66:1324-31.
] [Full text]
Wikan N, Suputtamongkol Y, Yoksan S, Smith DR, Auewarakul P. Immunological evidence of Zika virus transmission in Thailand. Asian Pac J Trop Med 2016;9:141-4.
Wiwanitkit S, Wiwanitkit V. Afebrile, asymptomatic and non-thrombocytopenic Zika virus infection: Don't miss it! Asian Pac J Trop Med 2016;9:513.
San K, Rajadan V. Seroprevalence of Zika virus in Cambodia: A preliminary report. Adv Lab Med Int 2016; 6:37-40.
Joob B, Wiwanitkit V. Incidence of Guillain-Barré syndrome among Zika virus infected cases: A report from Thailand. Arq Neuropsiquiatr 2018;76:63.